Abstract: Tuberculin-skin-test (TST) is widely used for the diagnosis of Tuberculosis. Negative TSTs are occasionally found in individuals vaccinated or infected by Mycobacterium tuberculosis. We show that false negative results are due to a lack of the Tuberculin-specific immune response as replacing tuberculin by unselected M. tuberculosis antigens improved the efficiency of the assay.
The tuberculin skin test (TST) is commonly used to help diagnosis of Mycobacterium Tuberculosis infection [2] . Purified protein derivative from M. Tuberculosis (PPD), also called Tuberculin, is injected intradermally, and the induction of a positive skin reaction is generally considered to indicate a latent or active TB, depending on the level of the skin reaction. In addition, positive tests are also found in patients after vaccination with Bacille Calmette-Guerin (BCG), or exposure to environmental mycobacteria. Negative test results may yet occur in a proportion of patients with active TB (10 to 25%) [3, 4] . These negative tests may find a biological explanation, as peripheral blood mononuclear cells (PBMC) from TB patients stimulated with Tuberculin (or PPD), release lower levels of IFN-and IL-12 compared to PPD responsive (i.e. TST-positive) healthy subjects [5] . Qualitative TST responses may vary depending on the clinical presentation of TB, especially in children. Finally, it has been established that there is no relationship between tuberculin skin-reactivity, and protection of vaccinated individuals against the development of active Tubercu-*Address correspondence to this author at the Department "Molecular Mechanisms of Mycobacterial Infections", Team "Molecular Physiology of Mycobacterial Granulomas", IPBS-CNRS UMR5089, 205, route de Narbonne, 31077 Toulouse cedex, France; Tel: (33) 5 61 17 54 63; Fax: (33) 5 61 17 59 94; E-mail: frederic.altare@ipbs.fr § These authors contributed equally to the work. losis [6] . Thus, not only the TST does not distinguish between Tuberculosis infection and BCG vaccination, but hence it does not witness a mycobacterial infection (in false negative individuals), and finally does not appear as a correlate of protection either.
Recent advances have improved the specificity of the immune identification of latent TB, using a combination of antigens (early secreted antigenic target 6 (ESAT-6), and culture filtrate protein 10 (CFP-10) encoded by the RD1 locus of M. Tuberculosis which is absent from most nonpathogenic mycobacteria, including Bacille-Calmette-Guerin). The sensitivity has also been improved by the ELISPOT (T SPOT-TB assay), an ex vivo assay quantifying the -Interferon produced by T-cells stimulated with ESAT-6 and CFP-10. On another hand, the performance of the recently proposed Quantiferon tests (based on whole blood interferon-release) has been shown to be negatively affected by patient's immune deficiency [7] . These serological and cytokine-based assays have yet to demonstrate an enhanced sensitivity and specificity when compared with the TST [8, 9] . In BCGvaccinated individuals, false positive results occur with all these tests, and false negative tests due to anergy or immune deficiency are widely recognised [10] [11] [12] . Moreover, cost will be a critical factor in determining the global use of these new assays [13] .
Pai and colleagues suggest combining the TST andinterferon assays to increase the sensitivity of the PPD-test and the specificity of RD1 antigens. This combination was used to confirm that the BCG vaccination gave significant protection against TB in children [14] . Yet, due to the numerous disadvantages of the TST previously discussed, we wondered whether we could find a better antigen than the Tuberculin to be used to give a more specific delayed-type hyper-sensitivity (DTH) reaction that could work in any individual. In this study, we thus investigated the possibility to replace Tuberculin by a more complex mixture of M. Tuberculosis (strain H 37 Rv) antigens, obtained by mechanic disruption of the bacilli, which could possibly avoid false negative results. We used an in vitro model of human granulomas to compare the reactivity of human immunity to PPD and M. Tuberculosis antigens. This model reproduces in vitro a delayed-type hypersensitivity (DTH) reaction, as does the TST in vivo. This reaction is produced by the incubation of PBMC from healthy volunteers with sepharose beads coated with mycobacterial antigens, which produces a granuloma-like structure characteristic of the immune response to M. Tuberculosis [15] [16] [17] .
Human blood samples were collected with informed consent from volunteers who had been BCG-vaccinated in infancy, and tested for their reactivity to PPD. For this purpose, PBMC from 100 volunteers (age 35-58, M/F: 61/39), including 85 PPD-positive individuals (Tubertest ® 5U, 0.1ml) and 15 PPD-negative individuals, were isolated, incubated with beads coated with PPD, or M. Tuberculosis extracts (prepared as described by Puissegur and colleagues [16] ), glycin-coated beads serving as negative control for non specific reaction. The ability of the different individuals to develop a granulomatous reaction around the different beads was followed by optical microscopy (data not shown) and scanning electron microscopy ( Fig. 1) .
As expected, granulomas were found for PPD-responders (TST > 5mm), both around beads coated with PPD (Fig.  1A) , and beads covered with M. Tuberculosis extracts (Fig.  1B) . In the 15 PPD-nonresponders (TST <5mm), no granulomas were ever found after incubation with PPD-coated beads (Fig. 1D) , but important granulomatous reaction developed in response to M. Tuberculosis extracts (Fig. 1E) . No cellular recruitment was observed with the negative control glycin-coated beads (Fig. 1C,F) . A quantification of the granulomatous response has been possible by the definition of a granuloma index (Fig. 2A,B,C) . The respective proportions of granulomas typical for each index has been determined for every TST-individual and presented in comparison to the index proportions of a representative TST+ volunteer (Fig. 2D) .
Noteworthy, the granulomatous response observed against M. Tuberculosis extracts is specific of the anti-mycobacterial response as no granulomatous response can be observed against E. Coli antigens, as previously described [16] .
Nowadays, the TST remains the most widely used test worldwide to determine whether an individual has an immunological reactivity against mycobacterial antigens and for the diagnosis of TB. Pai and colleagues [14] suggested a combined use of PPD and a T-cell based ELISpot, using ESAT-6 and CFP-10 as antigens, for the diagnosis of latent TB. Here, we point out that the absence of response to PPD doesn't necessarily mean an energy to M. Tuberculosis antigens, but rather a selective defect in the response to PPD of given individuals. In this study, we have shown that PBMC from all subjects who have been vaccinated in childhood, are able to respond in vitro to M. Tuberculosis complex extracts by the induction of a DTH response, whatever their ability to react to PPD. We could yet not determine the specific antigens from M. Tuberculosis complex extracts, responsible for the induction of the DTH response. Our model of in vitro granulomas using beads coated with purified antigens from M. Tuberculosis such as ESAT-6 and CFP-10, could improve, in combination with the ELISPOT assay, the efficiency and reliability of the diagnosis of tuberculosis. 
